

7.01.136		Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension	
Original Policy Date:	March 30, 2015	Effective Date:	November 1, 2021
Section:	7.0 Surgery	Page:	Page 1 of 17

Policy Statement

Radiofrequency ablation of the renal sympathetic nerves is considered **investigational** for the treatment of resistant hypertension.

NOTE: Refer to [Appendix A](#) to see the policy statement changes (if any) from the previous version.

Policy Guidelines

Coding

The following are CPT category III codes for this procedure:

- **0338T:** Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral
- **0339T:** Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral

These CPT category III codes cannot be reported with codes 36251, 36252, 36253, and 36254.

Description

Radiofrequency ablation (RFA) of the renal sympathetic nerves is thought to decrease both the afferent sympathetic signals from the kidney to the brain and the efferent signals from the brain to the kidney. This procedure decreases sympathetic activation, decreases vasoconstriction, and decreases activation of the renin-angiotensin system. Radiofrequency ablation of the renal sympathetic nerves may act as a nonpharmacologic treatment for hypertension and has been proposed as a treatment option for patients with resistant hypertension.

Related Policies

- N/A

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

No RFA devices have been approved by the U.S. Food and Drug Administration (FDA) for ablation of the renal sympathetic nerves as a treatment for hypertension. Several devices have been developed for this purpose and are in various stages of application for the FDA approval (FDA product code: DQY):

- Symplicity™ Renal Denervation System (Medtronic). In April 2018, the FDA approved an investigational device exemption pivotal trial, SPYRAL HTN (NCT02439749). The trial is randomized and sham-controlled and is designed to evaluate the RFA device as an alternative to exercise or lifestyle modification in patients with uncontrolled hypertension not treated with medication. Bohm et al (2020) has already published the 3-month results.⁴ The trial remains ongoing, however, with planned follow-up for 3 years for evaluation of long-term efficacy and safety. An additional randomized trial in patients with uncontrolled hypertension despite antihypertensive medication is ongoing (SPYRAL HTN-ON MED, NCT02439775).
- The EnligHTN™ Multi-Electrode Renal Denervation System (St. Jude Medical) is an RFA catheter using a 4-point multiablation basket design. In January 2014, the EnligHTN™ Renal Guiding Catheter was cleared for marketing by the FDA through the 510(k) process, based on substantial equivalence to predicate devices for the following indication: percutaneous use through an introducer sheath to facilitate a pathway to introduce interventional and diagnostic devices into the renal arterial vasculature.
- The Vessix™ Renal Denervation System (Boston Scientific; formerly the V2 renal denervation system, Vessix Vascular) is a combination of an RF balloon catheter and bipolar RF generator technologies, intended to permit a lower voltage intervention.
- In 2020, the FDA granted breakthrough therapy designation to 2 renal artery denervation systems - SoniVie's Therapeutic Intra-Vascular Ultrasound (TIVUS) System and Recor's Paradise Renal Denervation System - for treatment of patients with persistently elevated blood pressure.

Other RFA catheters (e.g., Thermocouple Catheter™ [Biosense Webster]) used for other types of ablation procedures (e.g., cardiac electrophysiology procedures) have been used off-label for RFA of the renal arteries.

Rationale

Background Resistant Hypertension

Hypertension is estimated to affect approximately 30% of the population in the U.S.¹ It accounts for a high burden of morbidity related to stroke, ischemic heart disease, kidney disease, and peripheral arterial disease. Resistant hypertension is defined as an elevated blood pressure, despite treatment with at least 3 antihypertensive agents at optimal doses. Resistant hypertension is also a relatively common condition, given the large number of individuals with hypertension. In large clinical trials of hypertension treatment, 20% to 30% of participants meet the definition for resistant hypertension, and in tertiary care hypertension clinics, the prevalence is estimated at 11% to 18%.¹ Resistant hypertension is associated with a higher risk for adverse outcomes such as stroke, myocardial infarction, heart failure, and kidney failure.

A number of factors may contribute to uncontrolled hypertension, and these should be considered and addressed in all patients with hypertension before labeling a patient resistant. These factors include nonadherence to medications, excessive salt intake, inadequate doses of medications, excess alcohol intake, volume overload, drug-induced hypertension, and other forms of secondary hypertension.² Also, sometimes it is necessary to address comorbid conditions (i.e., obstructive sleep apnea) to control blood pressure adequately.

Treatment

Treatment for resistant hypertension is mainly intensified drug therapy, sometimes with the use of nontraditional antihypertensive medications such as spironolactone and/or minoxidil. However, control of resistant hypertension with additional medications is often challenging and can lead to high costs and frequent adverse events of treatment. As a result, there is a large unmet need for additional treatments that can control resistant hypertension. Nonpharmacologic interventions for resistant hypertension include modulation of the baroreflex receptor and/or radiofrequency (RF) denervation of the renal nerves.

Radiofrequency Denervation of the Renal Sympathetic Nerves

Increased sympathetic nervous system activity has been linked to essential hypertension. Surgical sympathectomy has been shown to be effective in reducing blood pressure but is limited by the adverse events of surgery and was largely abandoned after effective medications for hypertension became available. The renal sympathetic nerves arise from the thoracic nerve roots and innervate the renal artery, the renal pelvis, and the renal parenchyma. Radiofrequency ablation (RFA) is thought to decrease both the afferent sympathetic signals from the kidney to the brain and the efferent signals from the brain to the kidney. This procedure decreases sympathetic activation, decreases vasoconstriction, and decreases activation of the renin-angiotensin system.³

The procedure is performed percutaneously with access at the femoral artery. A flexible catheter is threaded into the renal artery, and a controlled energy source, most commonly low-power RF energy, is delivered to the arterial walls where the renal sympathetic nerves are located. Once adequate RF energy has been delivered to ablate the sympathetic nerves, the catheter is removed.

Literature Review

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Radiofrequency Ablation

Clinical Context and Therapy Purpose

The purpose of radiofrequency ablation (RFA) in patients who have resistant hypertension is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of RFA improve the net health outcome in patients with resistant hypertension compared with continued medical therapy?

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is patients with hypertension that is resistant to standard medical management.

Interventions

The therapy being considered is RFA. Radiofrequency ablation is a minimally invasive procedure performed percutaneously with access at the femoral artery. A flexible catheter is threaded into the renal artery and a controlled low-power energy is delivered to the arterial walls to ablate the renal sympathetic nerves.

Comparators

The following therapy is currently being used to make decisions about treating those with resistant hypertension: continued medical therapy.

Outcomes

The general short-term outcomes of interest (follow-up to at least 6 months) are a change in systolic (SBP) and diastolic (DBP) blood pressure and medication use. Blood pressure measurements may include daytime ambulatory blood pressure, 24-hour average SBP, and office SBP.

A longer-term outcome of interest (follow-up to at least 3 years) is the effect on cardiovascular outcomes such as myocardial infarction and stroke.

Table 1. Outcomes of Interest for Individuals with Hypertension

Outcomes	Details	Timing
Morbid events	Outcomes of interest include adverse events such as end-stage renal disease, and embolic events resulting in end-organ damage, renal artery or other vascular complications, or hypertensive crisis.	≥ 30 days
Treatment-related morbidity	Outcomes of interest include decrease in daytime ambulatory SBP, nighttime SBP, and 24-hour average SBP	≥ 30 days

SBP: systolic blood pressure.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

Randomized Controlled Trials

DENERHTN Trial

Azizi et al (2015) published results of the Renal Denervation for Hypertension (DENERHTN) trial, a prospective, open-label RCT with blinded endpoint evaluation.⁵ The trial randomized 106 adults with confirmed resistant hypertension who had undergone 4 weeks of standardized triple antihypertensive therapy with sustained-release indapamide, ramipril (or irbesartan in cases of a cough), and amlodipine to either renal denervation or control. Both groups received standardized stepped-care antihypertensive treatment, which involved the sequential addition of spironolactone, bisoprolol, and sustained-release prazosin for SBP and DBP of 135 mm Hg or higher or 85 mm Hg or higher, respectively. Spironolactone could be started for home SBP and DBP of 170 mm Hg or higher or 105 mmHg or higher, respectively. The analysis was conducted

using a modified intention-to-treat design, after excluding 5 patients in the intervention group who were missing primary endpoint measurements. For the study's primary efficacy endpoint, the mean decrease in daytime ambulatory SBP after 6 months of follow-up was greater in the renal denervation group than in the control group (mean baseline-adjusted difference between groups, -5.9 mm Hg; 95% confidence interval [CI], -11.3 to -0.5 mm Hg; $p=.033$). There were similarly greater decreases in nighttime and 24-hour SBP in the renal denervation group than in the control group. Nighttime blood pressure control was achieved at 6 months in 31.3% of renal denervation patients (vs. 11.3% of controls; $p=.012$), and 24-hour ambulatory blood pressure control was achieved in 39.6% of renal denervation patients (vs. 18.9% of controls; $p=.013$). Rates of daytime blood pressure control did not differ significantly between groups. The number of antihypertensive treatments at 6 months also did not differ significantly between groups (mean, 5.25 for renal denervation patients vs. 5.36 for control patients; $p=.701$). Three renal denervation-related adverse events were reported (lumbar pain in 2 patients, mild groin hematoma in 1 patient).

Courand et al (2017) conducted a post hoc exploratory analysis using data from the DENERHTN trial to determine if abdominal aortic calcifications (AAC) had an impact on patients' response to renal denervation.⁶ Abdominal aortic calcification was measured in 90 patients. Analyses showed that patients with a lower AAC burden experienced larger decreases in daytime ambulatory SBP than patients who had a higher AAC burden.

Gosse et al (2017) also conducted an analysis to evaluate factors that may predict response to renal denervation.⁷ Comparing responders and nonresponders in the renal denervation group, average nighttime SBP and standard deviation were predictors of response to renal denervation. However, in the control group, these 2 variables did not discriminate between responders and nonresponders.

Prague-15 Study

Rosa et al (2015) reported on results of the Prague-15 study, an open-label RCT comparing renal sympathetic denervation with intensified pharmacologic treatment in patients who had resistant hypertension.⁸ Although trial enrollment was planned for 120 subjects with a 90% power in detecting a difference in treatment response between the 2 groups with an α of 0.05, the trial was prematurely halted after enrollment of 112 subjects (56 in each group), following the publication of the results of the Symplicity HTN-3 trial (discussed below). Patients in the renal denervation group were maintained on baseline medical therapy. Those in the control group received baseline medical therapy plus spironolactone. After 6 months, both groups demonstrated significant reductions in 24-hour average SBP (-8.6 mm Hg, $p<.001$ [vs. baseline] for renal denervation patients; -8.1 mm Hg, $p=.001$ [vs. baseline] for control patients). After 6 months, there were no significant differences in the absolute value or change in any of the blood pressure parameters reported between the renal denervation and control group.

Symplicity HTN-3

Bhatt et al (2014) published results of the Symplicity HTN-3 trial, a multicenter, single-blind, randomized, sham-controlled trial of renal denervation.⁹ Included patients had severe, resistant hypertension, with a SBP of 160 mm Hg or higher, on maximally tolerated doses of at least 3 antihypertensive medications of complimentary classes, 1 of which had to be a diuretic at an appropriate dose. Five-hundred thirty-five patients were randomized to renal denervation with the Symplicity renal denervation catheter or to renal angiography only (sham control).

Changes in antihypertensive medication were not allowed during the 6 month follow-up unless they were considered clinically necessary. The primary efficacy endpoint was the mean change in office SBP from baseline to 6 months in the denervation group compared with the sham control group. The secondary efficacy endpoint was the change in mean 24-hour ambulatory SBP at 6 months. The primary safety endpoint was a composite of major adverse events, defined as death from any cause, end-stage renal disease, an embolic event resulting in end-organ

damage, renal artery or other vascular complications, or hypertensive crisis within 30 days or new renal artery stenosis of more than 70% within 6 months.

At the 6-month follow-up point, there was no significant between-group difference in the change in office blood pressure. There was a change in SBP of -14.13 mm Hg in the denervation group versus -11.74 mm Hg in the sham control group, for an absolute difference of -2.39 mm Hg (95% CI, -6.89 to 2.12 mm Hg; $p=.26$; superiority margin, 5 mm Hg). At 6-month follow-up, the change in ambulatory blood pressure was -6.75 mm Hg in the denervation group and -4.79 mm Hg in the sham control group, for an absolute difference of -1.96 mm Hg (95% CI, -4.97 to 1.06 mm Hg; $p=.98$; superiority margin, 2 mm Hg). Major adverse event rates were similar between the denervation (1.4%) and control (0.6%) groups.

Strengths of this trial included its large size and blinded, sham-controlled design, which reduced the likelihood of a placebo effect. A limitation of the initial publication is that the follow-up period reported was relatively short, leading to an underdetection of a treatment benefit difference between the groups over time. The trial subjects, including those who do not cross over to renal denervation, will be followed for 5 years to assess longer-term outcomes.

Bakris et al (2014) reported on more detailed ambulatory blood pressure results from the Symplicity HTN-3 trial.¹⁰ The change in average 24-hour ambulatory SBP and DBP were as reported by Bhatt et al.⁹ There were no significant differences in change in ambulatory blood pressure between the renal denervation and control groups for any of the prespecified subgroup analyses. Included among these prespecified subgroup analyses were the presence of coexisting diabetes, sex, race, body mass index of 30 kg/m² or more, estimated glomerular filtration rate of 60 mL/min/1.73 m² or more, age of 60 years or older, or any medication change during the study.

Bakris et al (2015) also reported on 12-month follow-up data from the Symplicity HTN-3 trial, including the original denervation group, the sham subjects who crossed over to renal denervation, and the sham subjects who did not cross over.¹¹ The 12-month follow-up data were available for 319 of 361 denervation subjects and 48 of 101 non-crossover subjects, and 6-month denervation follow-up was available for 93 of 101 crossover subjects. At the 12-month follow-up, the changes in office SBP compared with baseline (-18.9 mm Hg) were significantly greater than at the 6-month follow-up in the renal denervation group (-15.5 mm Hg; $p=.025$). However, there were no significant differences in ambulatory blood pressure monitoring between the 12- and 6-month results in the renal denervation group. In the crossover group, the 6-month drop-in office SBP and 24-hour ambulatory SBP were -17.7 mm Hg ($p<.001$ vs. baseline) and -9.2 mm Hg ($p<.001$ vs. baseline), respectively. In the non-crossover group, 48 subjects had 12-month data available. Among those, the change in office SBP from baseline to 6 months was -32.9 mm Hg; the change in office SBP from 6 to 12 months was an increase of 11.5 mm Hg, for an overall SBP drop from baseline to 12 months of -21.4 mm Hg.

Using pooled data from the Symplicity HTN-3 trial and the Global Symplicity Registry, Mahfoud et al (2017) investigated the response to renal denervation in patients with isolated systolic hypertension and patients with combined systolic-diastolic hypertension.¹² A total of 1103 patients were included in the analysis, 429 with isolated systolic hypertension and 674 with combined hypertension. At 6 months, SBP reduction in patients with combined hypertension was -18.7 mm Hg compared with -10.9 mm Hg in patients with isolated systolic hypertension ($p<.001$).

Additional analyses from Symplicity HTN-3 have reported on the effects of renal denervation on nocturnal blood pressure and cardiac physiology and analyses of population subgroups.^{13,14,15}

Symplicity HTN-2 and Symplicity HTN-Japan

Symplicity HTN-2 was a multicenter, unblinded RCT (2010) evaluating renal sympathetic denervation and standard pharmacologic treatment for patients with resistant hypertension.¹⁶ A total of 106 patients with an SBP of at least 160 mm Hg, despite 3 or more antihypertensive

medications, were enrolled. Patients were followed for 6 months with the primary endpoint being the between-group difference in the change in blood pressure during the trial. Secondary outcomes included a composite outcome of adverse cardiovascular events and adverse events of treatment. Baseline blood pressure was 178/98 in the RFA group and 178/97 in the control group.

At 6-month follow-up, blood pressure reductions in the RFA group were 32 mm Hg (standard deviation, 23) SBP and 12 mm Hg (standard deviation, 11) DBP. In the control group, there was a 1-mm Hg increase in SBP and no change for DBP ($p < .001$ for both SBP and DBP differences). The percentage of patients who achieved an SBP of 140 mm Hg or less was 39% (19/49) in the RFA group compared with 6% (3/51) in the control group ($p < .001$). There was no difference in renal function, as measured by serum creatinine, between groups at the 6 month period. Three patients in the RFA group had adverse cardiovascular events compared with 2 in the control group ($p = NS$). Other serious adverse events requiring admission in the RFA group included 1 case each of nausea/vomiting, hypertensive crisis, transient ischemic attack, and hypotension.

One-year follow-up data from the Symplicity HTN-2 trial were reported by Esler et al (2012).¹⁷ This report included 47 of the 52 patients originally randomized to the RFA group, who were subsequently followed in an uncontrolled fashion after the 6-month follow-up. It also included 6 month follow-up of patients originally randomized to the control group, who were offered crossover to RFA after 6 months. Forty-six of 54 patients accepted crossover to RFA; 35 were available at 12 months. For the patients originally randomized to RFA, the decrease in blood pressure at 12 months was 28.1 mm Hg for SBP and 9.7 mm Hg for DBP. These decreases did not differ significantly from those reported at 6 months (31.7 mm Hg systolic, 11.7 mm Hg diastolic). For the crossover group, the decrease in blood pressure 6 months after renal denervation was 23.7 mm Hg systolic and 8.4 mm Hg diastolic. There were 2 procedural complications in the crossover group, 1 patient with a dissection of the renal artery and 1 patient with a hypotensive episode.

Three-year follow-up data from the Symplicity HTN-2 trial were reported by Esler et al (2014).¹⁸ Follow-up was available for 40 of 52 subjects in the initial RFA group and for 30 of 37 subjects in the initial control group who crossed over to renal denervation 6 months after enrollment. After 30 months, the mean change in SBP was -34 mm Hg (95% CI, -40 to -27 mm Hg; $p < .01$) and the mean change in DBP was -13 mm Hg (95% CI, -16 to -10 mm Hg; $p < .01$). The degree of blood pressure change was similar between the randomized and crossover subjects. Subjects in the initial RFA group had follow-up available at 36 months. At that point, the mean change in SBP was -33 mm Hg (95% CI, -40 to -25 mm Hg; $p < .01$) and the mean change in DBP was -14 mm Hg (95% CI, -17 to -10 mm Hg; $p < .01$). Beyond 12 months of follow-up, safety events included 5 hypertensive events requiring hospitalization; 1 case of mild transient acute renal failure due to dehydration; 2 episodes of atrial fibrillation requiring hospitalization; 1 case of acute renal failure due to acute interstitial nephritis deemed unrelated to renal denervation treatment; and 3 deaths deemed unrelated to the device or therapy.

The main limitations of the Symplicity HTN-2 trial were its small size, unblinded design, and a relatively short follow-up for the controlled portion of the trial. A trial with a sham control would have allowed a better determination of whether the treatment effect was due to a placebo effect, or other nonspecific effects of being in a trial. The 6 month follow-up reported for the controlled portion of the trial was too short to ascertain whether the reduction in blood pressure would reduce adverse cardiovascular outcomes such as myocardial infarction and stroke. The 12- and 36-month follow-up reports provided some insight into longer-term outcomes following the procedure, although comparison with a control group was no longer possible due to the crossover design.

It is unknown whether reinnervation of the renal sympathetic nerves occurs posttreatment. If it does, the efficacy of the procedure will diminish over time. The blood pressure change appears to be stable over the longer-term follow-up studies, suggesting that reinnervation did not occur in the 36-month follow-up.

Kario et al (2015) reported on results of the Symplicity HTN-Japan trial, which was an RCT comparing renal sympathetic denervation with standard pharmacotherapy in subjects with treatment-resistant hypertension.¹⁹ Enrollment was initially planned for 100 subjects, but the trial was halted early after results of the Symplicity HTN-3 trial were published, at which time 41 subjects (22 to renal denervation, 19 to control) had been randomized. At 6 months, the change in SBP in renal denervation subjects did not differ significantly from the change in SBP in control subjects (between-group difference, -8.6 mm Hg; 95% CI, -21.1 to 3.8 mm Hg; $p=.169$). No major adverse events occurred. The authors noted that the trial was underpowered due to the early termination.

SYMPATHY

De Jager et al (2017) conducted a trial in which patients with resistant hypertension were randomized to usual care based on European Society Hypertension guidelines ($n=44$) or usual care plus renal denervation ($n=95$) - the Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension (SYMPATHY) trial.²⁰ Six-month follow-up analyses showed no significant difference between groups in daytime SBP (2.0 mm Hg; 95% CI, -6.1 to 10.2 mm Hg), 24-hour SBP (1.0 mm Hg; 95% CI, -7.1 to 9.1 mm Hg), or office SBP (-8.2 mm Hg; 95% CI, -17.1 to 0.7 mm Hg).

De Jager et al (2018) evaluated medication adherence as a post hoc analysis of data from the SYMPATHY trial.²¹ Serum screening for blood pressure-lowering drugs was conducted on samples taken at baseline ($n=98$) and at the 6-month follow-up ($n=83$). Most patients (68%) were found to be nonadherent. Factors related to nonadherence were a higher number of prescribed blood pressure-lowering drugs, higher baseline blood pressure, and younger age. As adherence decreased, office blood pressure increased significantly.

Other Randomized Controlled Trials

Several smaller RCTs (N range, 18 to 81 patients) have compared renal denervation with drug therapy for the treatment of resistant hypertension, with inconsistent results.^{22,23,24,25,26,27,28} Although the majority of the unblinded trials demonstrated some significant improvements in blood pressure control with renal denervation,^{23,26,27,28} the more rigorous trials that used a double-blind, sham-controlled design to reduce the risk of a placebo effect showed no significant improvements with renal denervation.^{22,24,25}

Section Summary: Randomized Controlled Trials

Several RCTs have compared renal denervation with drug therapy for the treatment of resistant hypertension, with inconsistent results. The most rigorous evidence about the efficacy of renal denervation comes from the largest of these trials, the Symplicity HTN-3 trial, which used a single-blind, sham-controlled design to reduce the risk of a placebo effect and showed no significant improvements in blood pressure control with renal denervation at 6 months. Other smaller trials that used sham controls also showed no significant improvements in SBP for patients treated with renal denervation compared with controls. Other trials not using a sham control design, including the DENERHTN and Symplicity HTN-2 trials, did find a significant benefit in patients treated with renal denervation. Potential explanations for the differences in the treatment effect between the Symplicity HTN-3 trial and the unblinded trials may be a placebo effect or other nonspecific effects of participating in a trial. Alternatively, blood pressure control in the control arm might have been better in Symplicity HTN-3 trial than in earlier studies.

Systematic Reviews

Multiple systematic reviews with overlapping studies, 1 of which is a Cochrane review by Coppolino et al (2017),²⁹ have summarized the key RCTs evaluating renal denervation. The characteristics of the systematic reviews are summarized in Table 2, and the key results are summarized in Table 3. The overall results vary depending on the inclusion of earlier, unblinded studies and controlled but nonrandomized studies, with some systematic reviews reporting

significant improvements with renal denervation and some reporting no significant improvement.

The Cochrane review reported that none of the trials was designed to evaluate clinical endpoints as primary outcomes.²⁹ The evidence for clinical endpoints (e.g., all-cause mortality, hospitalization, cardiovascular events) was of low-quality. Comparisons of clinical outcomes in sham versus renal denervation groups showed no significant differences between groups in myocardial infarction (relative risk, 1.3; 95% CI, 0.5 to 3.8), ischemic stroke (relative risk, 1.1; 95% CI, 0.4 to 3.7), or unstable angina (relative risk, 0.6; 95% CI, 0.1 to 5.1).

Most analyses included 6-month follow-up measurements, while a review by Chen et al (2017),³⁰ calculated change in blood pressure for subgroups at 12-month follow-up. The 12-month analysis showed no difference at the longer follow-up.

Table 2. Characteristics of Systematic Review of Controlled Trials Assessing Renal Denervation

Study	Dates	Trials	N (Range)	Design	Duration, mo
Pappaccogli et al (2018) ³¹	2010-2016	11	1236 (19-535)	RCT, CT	6
Coppolino et al (2017) ²⁹	2010-2016	12	1149 (16-535)	RCT, CT	6
Chen et al (2017) ³⁰	2010-2016	9	1068 (19-535)	RCT	6
Fadl Elmula et al (2017) ³²	2010-2017	10	1174 (19-524)	RCT, CT	6
Sun et al (2016) ³³	2010-2015	9	2932 (67-622)	RCT, CT	6
Zhang et al (2016) ³⁴	2013-2015	11	1160 (19-535)	RCT, CT	6
Yao et al (2016) ³⁵	2010-2015	8	1059 (19-535)	RCT	6
Fadl Elmula et al (2015) ³⁶	2010-2015	7	985 (20-535)	RCT	6

CT: controlled trial; RCT: randomized controlled trial.

Table 3. Systematic Review Results at 6-Month Follow-Up for Controlled Trials Assessing Renal Denervation

Study	Treatment	Comparator	Trials	Outcomes	SMD, mm Hg	95% CI, mm Hg	p	I ² , %
Pappaccogli et al (2018) ³¹	RD	Control	9	Office SBP	-3.5	-13.0 to 6.1	NS	90
			9	Office DBP	-2.8	-6.0 to 0.4	NS	74
			10	ASBP	-1.8	-4.5 to 0.9	NS	47
			10	ADBP	-0.6	-2.3 to 1.2	NS	63
Coppolino et al (2017) ²⁹	RD	Control	5	24-h SBP	0.3	-3.7 to 4.3	NS	NR
			4	24-h DBP	0.9	-4.5 to 6.4	NS	NR
			6	Office SBP	-4.1	-15.3 to 7.1	NS	NR
			5	Office DBP	-1.3	-7.3 to 4.7	NR	NR
Chen et al (2017) ³⁰	RD	Control	9	24-h SBP	-1.1	-4.7 to 2.5	.55	67
			7	Office SBP	-2.5	-12.9 to 7.8	.63	90
Fadl Elmula et al (2017) ³²	RD	Control	8	Office SBP	-3.6	-12.8 to 5.6	.45	NR
			10	24-h SBP	-1.0	-4.3 to 2.3	.54	NR
Sun et al (2016) ³³	RD	Control	9	Office SBP	-12.81	-22.77 to -2.85	.01	92
			8	Office DBP	-5.56	-8.15 to -2.97	<.001	63
Zhang et al (2016) ³⁴	RD	Control	11	Office SBP	-13.9	-21.17 to -6.63	<.001	93
Yao et al (2016) ³⁵	RD	Control	8	Office SBP	-8.23	-16.86 to 0.39	NR	93
			8	Office DBP	-3.77	-7.21 to -0.32	NR	90
Fadl Elmula et al (2015) ³⁶	RD	Control	15	Office SBP	-4.89	-20.9 to 11.1	.47	91.7

ADBP: ambulatory diastolic blood pressure; ASBP: ambulatory systolic blood pressure; CI: confidence interval; DBP: diastolic blood pressure; NR: not reported; NS: not significant; RD: renal denervation; SBP: systolic blood pressure; SMD: standardized mean difference.

Several other systematic reviews have also included RCTs and nonrandomized studies. Kwok et al (2014) published a systematic review on renal denervation that included 3 RCTs (the Symplicity HTN-3 trial, the Symplicity HTN-2 trial, and Pokushalov et al (2012), described in the Randomized Controlled Trials section), 8 prospective observational studies, and 1 observational study with matched controls.³⁷ Similarly, Pancholy et al (2014) published a meta-analysis of renal denervation that included the same 3 RCTs, along with 2 non-RCTs.³⁸ Other systematic reviews

and meta-analyses, including those by Davis et al (2013)³⁹ and Shantha et al (2015),⁴⁰ did not include the Symplicity HTN-3 trial or subsequently reported RCTs.

Nonrandomized Comparative Studies

Several nonrandomized studies with a control group have been published. Populations from some of these studies overlap to a large extent with the Symplicity HTN-2 trial. Additional cases may have been added to the study population using the same eligibility criteria, and only a small number of control patients were included in the analyses. Thus, these comparisons are not considered randomized. These studies examined different physiologic outcomes in addition to changes in blood pressure.

Other nonrandomized comparative studies exist. Given the multiple randomized studies, these studies add little to the overall body of evidence and are not discussed further here.^{41,42,43,44}

Summary of Evidence

For individuals who have hypertension resistant to standard medical management who receive RFA of the renal sympathetic nerves, the evidence includes numerous RCTs, numerous systematic reviews of the RCTs, as well as multiple nonrandomized comparative studies and case series. Relevant outcomes are symptoms, change in disease status, morbid events, medication use, and treatment-related morbidity. The largest trial, the Symplicity HTN-3 trial, used a sham-controlled design to reduce the likelihood of placebo effect and demonstrated no significant differences between renal denervation and sham control patients in office-based or ambulatory blood pressure at 6-month follow-up. The Symplicity HTN-3 results were in contrast to other studies not using a sham control design, including Symplicity HTN-2 and the Renal Denervation for Hypertension (DENERHTN) trial, which reported efficacy in reducing blood pressure over a 6 month period compared with a control group. However, results from Symplicity HTN-3 have been supported by a number of subsequent smaller sham-controlled trials. Meta-analyses of the RCTs have also reported inconsistent findings, with most analyses showing no significant benefit in blood pressure measurements following RFA. Single-arm studies with overlapping populations have reported improvements in blood pressure and related physiologic parameters, such as echocardiographic measures of left ventricular hypertrophy, that appear to be durable up to 24 months of follow-up. The strongest evidence comes from sham-controlled trials, the largest of which found no significant benefits with renal denervation. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Heart Association et al

The American Heart Association, American College of Cardiology, and American Society of Hypertension (2015) issued joint guidelines on the treatment of hypertension in patients with coronary artery disease.⁴⁵ The guidelines noted the Symplicity HTN-3 trial did not find a significant benefit from renal denervation and stated that additional randomized controlled trials would be needed.

The American Heart Association, American College of Cardiology, and 9 additional specialty societies (2018) published joint guidelines on the prevention, detection, evaluation, and

management of high blood pressure in adults.⁴⁶ In discussing resistant hypertension, the guidelines indicated that studies using catheter ablation of renal sympathetic nerves "have not provided sufficient evidence to recommend the use of these devices."

The American Heart Association (AHA; 2018) published a Scientific Statement on the detection, evaluation, and management of resistant hypertension.⁴⁷ The AHA Statement discussed the lack of benefit found in the Symplicity HTN-3 trial, as well as its methodological limitations. The statement also referred to the more recent positive data from the SPYRAL HTN-OFF MED trial, but noted that because the enrolled patients did not have resistant hypertension, "at best, this represents a proof-of-principle study demonstrating the role of the renal sympathetic nervous system in hypertension." The statement concluded that "the role of device-based sympatholytic treatments, as with renal denervation and baroreceptor stimulation, awaits clarification."

Eighth Joint National Committee

The Eighth Joint National Committee (2014), which was appointed to provide recommendations on hypertension treatment, published an evidence-based guideline on the management of hypertension in adults.⁴⁸ These recommendations did not discuss the use of renal denervation.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in Table 4.

Table 4. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT02439775	Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy (SPYRAL HTN-ON MED)	340	Jul 2025
NCT01673516	Effect of Renal Sympathetic Denervation on Resistant Hypertension and Cardiovascular Hemodynamic in Comparison to Intensive Medical Therapy Utilizing Impedance Cardiography	60	Aug 2022
NCT02439749	Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications (SPYRAL HTN-OFF MED)	366	Mar 2023
NCT04307836	A Prospective, Multicenter, No-treatment Controlled, Randomized, Open-label, Pivotal Study to Evaluate the Safety and Efficacy of DENEX, Renal Denervation Therapy, in Patients with Hypertension on no or 1-3 Antihypertensive Medications	140	Jan 2023
Unpublished			
NCT01522430	Denervation of Renal Sympathetic Activity and Hypertension Study	120	Dec 2016 (unknown)
NCT01932450	A Randomized, Open-label Study Investigating the Effect of Bilateral Renal Artery Sympathetic Denervation by Catheter-based Radiofrequency Ablation on Blood Pressure and Disease Progression in Autosomal Dominant Polycystic Kidney Disease	100	Jul 2015 (unknown)
NCT01628172 ^a	Renal Sympathetic Denervation for the Management of Chronic Hypertension	96	Mar 2014 (completed)

NCT: national clinical trial.

References

1. Acelajado MC, Calhoun DA. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. *Cardiol Clin*. Nov 2010; 28(4): 639-54. PMID 20937447
2. Doumas M, Papademetriou V, Douma S, et al. Benefits from treatment and control of patients with resistant hypertension. *Int J Hypertens*. Dec 22 2010; 2011: 318549. PMID 21234402
3. Zile MR, Little WC. Effects of autonomic modulation: more than just blood pressure. *J Am Coll Cardiol*. Mar 06 2012; 59(10): 910-2. PMID 22381426
4. Bohm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. *Lancet*. May 02 2020; 395(10234): 1444-1451. PMID 32234534
5. Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. *Lancet*. May 16 2015; 385(9981): 1957-65. PMID 25631070
6. Courand PY, Pereira H, Del Giudice C, et al. Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial. *J Am Heart Assoc*. Oct 10 2017; 6(10). PMID 29018027
7. Gosse P, Cremer A, Pereira H, et al. Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension). *Hypertension*. Mar 2017; 69(3): 494-500. PMID 28115517
8. Rosa J, Widimsky P, Tousek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. *Hypertension*. Feb 2015; 65(2): 407-13. PMID 25421981
9. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. *N Engl J Med*. Apr 10 2014; 370(15): 1393-401. PMID 24678939
10. Bakris GL, Townsend RR, Liu M, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. *J Am Coll Cardiol*. Sep 16 2014; 64(11): 1071-8. PMID 24858423
11. Bakris GL, Townsend RR, Flack JM, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. *J Am Coll Cardiol*. Apr 07 2015; 65(13): 1314-1321. PMID 25835443
12. Mahfoud F, Bakris G, Bhatt DL, et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. *Eur Heart J*. Jan 07 2017; 38(2): 93-100. PMID 28158510
13. Kario K, Bhatt DL, Brar S, et al. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. *Hypertension*. Dec 2015; 66(6): 1130-7. PMID 26558819
14. Lu D, Wang K, Liu Q, et al. Reductions of left ventricular mass and atrial size following renal denervation: a meta-analysis. *Clin Res Cardiol*. Aug 2016; 105(8): 648-656. PMID 26838292
15. Flack JM, Bhatt DL, Kandzari DE, et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. *J Am Soc Hypertens*. Oct 2015; 9(10): 769-779. PMID 26362830
16. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. *Lancet*. Dec 04 2010; 376(9756): 1903-9. PMID 21093036
17. Esler MD, Krum H, Schlaich M, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. *Circulation*. Dec 18 2012; 126(25): 2976-82. PMID 23248063

18. Esler MD, Bohm M, Sievert H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPPLICITY HTN-2 randomized clinical trial. *Eur Heart J*. Jul 2014; 35(26): 1752-9. PMID 24898552
19. Kario K, Ogawa H, Okumura K, et al. SYMPPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients -. *Circ J*. 2015; 79(6): 1222-9. PMID 25912693
20. de Jager RL, de Beus E, Beeftink MM, et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. *Hypertension*. Apr 2017; 69(4): 678-684. PMID 28264922
21. de Jager RL, van Maarseveen EM, Bots ML, et al. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. *Br J Clin Pharmacol*. Jan 2018; 84(1): 18-24. PMID 28815689
22. Schmieder RE, Ott C, Toennes SW, et al. Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV. *J Hypertens*. Mar 2018; 36(3): 680-689. PMID 29035942
23. Oliveras A, Armario P, Clara A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. *J Hypertens*. Sep 2016; 34(9): 1863-71. PMID 27327441
24. Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. *J Hypertens*. Aug 2016; 34(8): 1639-47. PMID 27228432
25. Desch S, Okon T, Heinemann D, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. *Hypertension*. Jun 2015; 65(6): 1202-8. PMID 25824248
26. Schneider S, Promny D, Sinnecker D, et al. Impact of sympathetic renal denervation: a randomized study in patients after renal transplantation (ISAR-denerve). *Nephrol Dial Transplant*. Nov 2015; 30(11): 1928-36. PMID 26333545
27. Fadl Elmula FE, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. *Hypertension*. May 2014; 63(5): 991-9. PMID 24591332
28. Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. *J Am Coll Cardiol*. Sep 25 2012; 60(13): 1163-70. PMID 22958958
29. Coppolino G, Pisano A, Rivoli L, et al. Renal denervation for resistant hypertension. *Cochrane Database Syst Rev*. Feb 21 2017; 2: CD011499. PMID 28220472
30. Chen XH, Kim S, Zeng XX, et al. Account for Clinical Heterogeneity in Assessment of Catheter-based Renal Denervation among Resistant Hypertension Patients: Subgroup Meta-analysis. *Chin Med J (Engl)*. Jul 05 2017; 130(13): 1586-1594. PMID 28639575
31. Pappaccogli M, Covella M, Berra E, et al. Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies. *High Blood Press Cardiovasc Prev*. Jun 2018; 25(2): 167-176. PMID 29752703
32. Fadl Elmula FEM, Feng YM, Jacobs L, et al. Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. *Blood Press*. Aug 2017; 26(4): 195-203. PMID 28443356
33. Sun D, Li C, Li M, et al. Renal Denervation vs Pharmacotherapy for Resistant Hypertension: A Meta-Analysis. *J Clin Hypertens (Greenwich)*. Aug 2016; 18(8): 733-40. PMID 26619813
34. Zhang X, Wu N, Yan W, et al. The effects of renal denervation on resistant hypertension patients: a meta-analysis. *Blood Press Monit*. Aug 2016; 21(4): 206-14. PMID 26901340
35. Yao Y, Zhang D, Qian J, et al. The effect of renal denervation on resistant hypertension: Meta-analysis of randomized controlled clinical trials. *Clin Exp Hypertens*. 2016; 38(3): 278-86. PMID 27018652
36. Fadl Elmula FE, Jin Y, Yang WY, et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. *Blood Press*. 2015; 24(5): 263-74. PMID 26194721

37. Kwok CS, Loke YK, Pradhan S, et al. Renal denervation and blood pressure reduction in resistant hypertension: a systematic review and meta-analysis. *Open Heart*. NA 2014; 1(1): e000092. PMID 25332808
38. Pancholy SB, Shantha GP, Patel TM, et al. Meta-analysis of the effect of renal denervation on blood pressure and pulse pressure in patients with resistant systemic hypertension. *Am J Cardiol*. Sep 15 2014; 114(6): 856-61. PMID 25084693
39. Davis MI, Filion KB, Zhang D, et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. *J Am Coll Cardiol*. Jul 16 2013; 62(3): 231-241. PMID 23644092
40. Shantha GP, Pancholy SB. Effect of renal sympathetic denervation on apnea-hypopnea index in patients with obstructive sleep apnea: a systematic review and meta-analysis. *Sleep Breath*. Mar 2015; 19(1): 29-34. PMID 24839239
41. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. *J Am Coll Cardiol*. Mar 06 2012; 59(10): 901-9. PMID 22381425
42. Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. *Hypertension*. Aug 2012; 60(2): 419-24. PMID 22733462
43. Ukena C, Mahfoud F, Kindermann I, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. *J Am Coll Cardiol*. Sep 06 2011; 58(11): 1176-82. PMID 21884958
44. Ewen S, Mahfoud F, Linz D, et al. Effects of renal sympathetic denervation on exercise blood pressure, heart rate, and capacity in patients with resistant hypertension. *Hypertension*. Apr 2014; 63(4): 839-45. PMID 24420550
45. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. *Circulation*. May 12 2015; 131(19): e435-70. PMID 25829340
46. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. Jun 2018; 71(6): 1269-1324. PMID 29133354
47. Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. *Hypertension*. Nov 2018; 72(5): e53-e90. PMID 30354828
48. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. Feb 05 2014; 311(5): 507-20. PMID 24352797
49. Blue Cross Blue Shield Association. Medical Policy Reference Manual, No. 7.01.136 (September 2021).

Documentation for Clinical Review

- No records required

Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement

policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.

Type	Code	Description
CPT®	0338T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral
	0339T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral
HCPCS	None	

Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

Effective Date	Action
03/30/2015	BCBSA Medical Policy adoption
11/01/2016	Policy revision without position change
11/01/2017	Policy revision without position change
11/01/2018	Policy revision without position change
12/16/2019	Policy revision without position change
12/01/2020	Annual review. No change to policy statement. Literature review updated.
11/01/2021	Annual review. No change to policy statement. Literature review updated.

Definitions of Decision Determinations

Medically Necessary: Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member's illness, injury, or disease.

Investigational/Experimental: A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

Split Evaluation: Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

Prior Authorization Requirements (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at www.blueshieldca.com/provider.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.

Appendix A

POLICY STATEMENT (No changes)	
BEFORE	AFTER
<p>Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension 7.01.136</p> <p>Policy Statement: Radiofrequency ablation of the renal sympathetic nerves is considered investigational for the treatment of resistant hypertension.</p>	<p>Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension 7.01.136</p> <p>Policy Statement: Radiofrequency ablation of the renal sympathetic nerves is considered investigational for the treatment of resistant hypertension.</p>